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Introduction
The advancement of knowledge on lymphomas is at times
bewildering. As shown below, the amount of new data is
enormous, and this is only a selection of studies that are
already or in the near future relevant for hematopatholo-
gists. I hope that the length of this overview does not scare
off the readership, since there are many interesting studies
presented from all over the world and from many different
journals.
Biology of lymphoma
The focus of research in many areas of cancer is getting
knowledge from the biology of cancer into clinical practice
by developing targeted therapies in association with
methods that identify patients that will benefit from these
new approaches. The last few months’ several studies
indicate potential targets in lymphomas, and we will see in
the next couple of years how this will lead to improved
treatment.
Hodgkin lymphoma
The rosetting of CD4+CD26− Tcells in classical Hodgkin’s
lymphoma (cHL) is a well-known phenomenon, but little is
known about the gene expression profile and significance
of these T cells. A higher percentage of CD4+CD26− T
cells is present in nodular sclerosis Hodgkin lymphoma
(NSHL) than in reactive lymph nodes. The resting CD4+
CD26− T cells in NSHL showed higher mRNA levels of
CD25, CTLA4, OX40, and CCR4 compared with lymph
nodes, supporting a regulatory T cell (Treg) type, and this
was validated by immunohistochemistry. Moreover, these
cells showed low or no expression of the Th1- or Th2-
related cytokines IL-2, IFN-gamma, IL-13, IL-12B, IL-4,
and IL-5 and the chemoattractant receptor CRTH2. Besides
Tregs, Th17 cells may exist in NSHL based on the
significantly higher IL-17 mRNA level for both T cell
populations in NSHL. Upon stimulation in vitro, lack of
upregulation of mRNA levels of most cytokine genes
indicated an anergic character for the CD4+CD26− T cell
subset. Anergy fits with the Treg profile of these cells,
probably explaining the immunosuppressive mechanism
involved in NSHL [1].
PRDM1/Blimp-1, a master regulator in terminal B cell
differentiation, has been recently identified as a tumor
suppressor target for mutational inactivation in diffuse large
B cell lymphomas (DLBCL) of the activated B cell type.
PRDM1/Blimp-1 is also a target for microRNA (miRNA)-
mediated downregulation by miR-9 and let-7a in Hodgkin/
Reed–Sternberg (HRS) cells of Hodgkin lymphoma (HL).
These miRNAs target specific binding sites in the 3′
untranslated region of PRDM1/Blimp-1 mRNA and high
levels of miR-9 and let-7a in HL cell lines correlated with
low levels of PRDM1/Blimp-1. Similar to their in vitro
counterparts, the majority of HRS cells in primary HL cases
showed weak or no PRDM1/Blimp-1 expression. MiRNA-
mediated downregulation of PRDM1/Blimp-1 may contrib-
ute to the phenotype maintenance and pathogenesis of HRS
cells by interfering with normal B cell terminal differenti-
ation, thus representing a novel molecular lesion, as well as
a potential therapeutic target in HL [2].
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binding protein regulated by an AP1-dependent enhancer
in HRS cells and its expression affects the microenviron-
ment in HL. Rodig et al. studied the expression of GAL1
and AP1 pathway proteins in 225 cases of various
lymphomas and found that Gal1 is selectively expressed
by Reed–Sternberg cells in >90% of primary cHLs and
ALCL, in concordance with the activated AP1 component,
c-jun. In contrast, DLBCL, primary mediastinal large B cell
lymphoma, and another Hodgkin-related entity, nodular
lymphocyte-predominant Hodgkin lymphoma (NLPHL), do
not express Gal1 [3].
B cell lymphomas
In my previous review of the literature [4], I wrote that
predictive markers are only limitedly available for lympho-
mas. This may soon change, since Yang at al. demonstrate
that Src tyrosine kinase inhibition by dasatinib has
antilymphoma effects because it inhibits cell growth in five
of seven DLBCL cell lines. Compared to resting B cells,
DLBCL has increased tyrosine phosphorylation activities.
Dasatinib inhibits phosphorylation of several Src family
kinase members, but in all cell lines regardless of their
proliferative response to the drug. In contrast, the activity of
two downstream signaling molecules, Syk and phospholipase
Cgamma2 (PLCgamma2), are well-correlated with cell line
sensitivity to dasatinib, suggesting that these molecules are
crucial in mediating the proliferation of activated lymphoma
cells.Thesefindingsshowthatdasatinibisapotentiallyuseful
therapy for DLBCL but also indicate that Syk and
PLCgamma2 are potential biomarkers to predict dasatinib
therapeutic response [5], a situation very similar to that of
KRAS wild type predicting response to EGFR blocking in
colorectal cancer.
Tissue inhibitor of metalloproteinase-1 (TIMP1) is a
survival factor of germinal center (GC) B cells, and its
overexpression is correlated with aggressive B cell lym-
phomas and cHL. TIMP1 downregulates B cell receptor
and BCL6 and activates interleukin (IL)-6, IL-10/signal
transducer, and activator of transcription-3 (STAT3) signal-
ing in GC B cells. Kim et al. show that TIMP1 upregulates
cell surface CD44 (standard and variants 3 and 7–10) and
induces the activity and nuclear localization of SHP1 in an
Epstein–Barr virus (EBV)-negative Burkitt lymphoma (BL)
cell line, the neoplastic counterpart of GC centroblasts,
suggesting that TIMP1 functions as a differentiating and
survival factor of GC B cells by modulating CD44 and
SHP1 in the late centrocyte/post-GC stage [6].
Increasing numbers of proteins are described that are
involved in lymphomagenesis and influencing them
might result in targeted therapies. Garrison et al. make
this point for PUMA which encodes a BH3-only
proapoptotic protein and which is targeted by p53. In a
mouse model, cell lines, and cases of BL, it is shown
that loss of PUMA frequently occurs, but that it can be
reactivated by inhibition of DNA methyltransferases [7].
Nyagol et al. studied the role of the HIV-encoded Tat
gene for inducing angiogenesis in HIV-associated lympho-
mas, since this may explain their aggressive behavior.
Angiogenic switch marks the beginning of tumor’s strategy
to acquire independent blood supply. VEGF receptors are
targeted by Tat protein from the HIV-1-infected cells due to
the similarity of the basic region of Tat to the angiogenic
factors (basic fibroblast growth factor, VEGF). VEGF
promoter activity was downregulated in vitro in cells
transfected with Tat. Reduced VEGF protein expression
in primary HIV-1-positive BL and DLBCL, compared to
the negative cases, supported the findings of promoter
downregulation from the cell lines. Microvascular density
assessed by CD34 expression was, however, higher in
HIV-1-positive than in HIV-1-negative tumors. These
results suggest that Tat has a wider angiogenic role,
besides the regulation of VEGF expression. Thus, target-
ing Tat protein itself and stabilizing transient silencing of
VEGF expression or use of monoclonal antibodies against
their receptors in the AIDS-associated tumors will open a
window for future explorable pathways in the manage-
ment of angiogenic phenotypes in the AIDS-associated
non-Hodgkin’s lymphomas (NHL) [8].
Since recently developed drugs that target the antifibro-
blast growth factor receptor 3 (FGFR3) pathway are being
tested in multiple myeloma in which about 15% cases carry
the t(4;14) resulting in overexpression of FGFR3, Larson et
al. analyzed 70 cases of malignant lymphoma. Only weak
to moderate expression was found in 12% of cases, so it is
unlikely that FGFR3 targeting is an effective treatment in
lymphomas as well [9].
FOXP1 is targeted by chromosome translocations in
mucosa-associated lymphoid tissue (MALT) lymphoma
and DLBCL where high-level protein expression is associ-
ated with poor prognosis but the incidence and nature of
FOXP1 abnormalities at both the genetic and protein levels
and their correlation in these lymphomas are not well-
established. Goatly et al. studied, by fluorescence in situ
hybridization (FISH) and immunohistochemistry, a very
large series (n=321) of extranodal marginal zone lympho-
mas and MALT lymphoma with a DLBCL component (n=
59), nodal DLBCL (n=64), and extranodal DLBCL (n=
151). FOXP1 translocation was found in eight MALT
lymphomas and three MALT lymphomas with DLBCL
with all positive cases originating in the stomach. In
DLBCL, the translocation was seen in five cases originating
in the stomach (two cases), tonsil (one case), large intestine
(one case), and lymph node (one case). Three copies of the
FOXP1 gene were observed in MALT lymphoma (17%),
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(32%), including cases with FOXP1 translocation (19%).
Immunohistochemistry showed strong/moderate FOXP1
staining in all the cases with FOXP1 translocation.
However, FOXP1 expression was independent of FOXP1
translocation or copy number changes so that mechanisms
other than translocation and copy number changes are also
responsible for FOXP1 overexpression in lymphoma [10].
Functional characterization of signaling pathways that
critically control mantle cell lymphoma (MCL) cell growth
and survival is relevant to designing new therapies for this
lymphoma. Hogan et al. analyzed the role of mdm2
aberrations in disrupting the p53 pathway in lymphoma-
genesis. At a physiological level, endogenous Pim-1 and
Pim-2 interact with endogenous Mdm2 and the Pim kinases
phosphorylate Mdm2 in vitro and in cultured cells at Ser
(166) and Ser(186), two previously identified targets of
other signaling pathways, including Akt. High levels of
Pim expression, as occurs in tumors, active, but not
inactive, Pim-1 or Pim-2 blocks the degradation of both
p53 and Mdm2 in a manner that is independent of Mdm2
phosphorylation, leading to increased p53 levels and,
proportionately, p53-dependent transactivation. Immunohis-
tochemical analysis of a cohort of 33 human MCL show
that elevated expression of Pim-1 occurs in 42% of cases
with elevated Pim-2 occurring in 9% of cases, all of which
also express Pim-1. Notably, elevated Pim-1 correlates with
elevated Mdm2 in MCL. These data are consistent with the
idea that Pim normally interacts with the p53 pathway but,
when expressed at pathological levels, like in MCL,
behaves as a classic dominant oncogene that stimulates a
protective response through the induction of the p53
pathway [11]. Dal et al. demonstrate that the constitutive
activation of Akt correlates with the expression of the
phosphorylated, inactive form of PTEN. Phosphatidyl-
inositol-3 kinase (PI3-K)/Akt or mammalian target of
rapamycin (mTOR) inhibition decreased the growth of both
primary MCL cultures and established cell lines and
antagonized the growth-promoting activity of CD40 trig-
gering and IL-4. These effects are mediated by nuclear
accumulation of the p27(Kip1) inhibitor induced by the
downregulation of the p45(Skp2) and Cks1 proteins, which
target p27(Kip1) for degradation. Moreover, Akt inhibition
downregulated cyclin D1 by promoting its proteasome-
dependent degradation driven by GSK-3. Intriguingly,
mTOR inhibition affected cyclin D1 proteolysis only in
MCL cells in which GSK-3 is under the direct control of
mTOR, suggesting that different MCL subsets could be
differently responsive to mTOR inhibition. Finally, PI3-K/Akt
inhibitors, but not rapamycin, induced variable levels of
caspase-dependent apoptosis and reduced telomerase activ-
ity. These results indicate that Akt and mTOR activation
have distinct functional relevance in MCL and suggest that
targeting Akt may result in more effective therapeutic effects
compared with mTOR inhibition [12].
Wang et al. were able to create a mouse model for MCL
that might help in further performing such studies. They
isolated primary MCL cells from spleen, lymph node, bone
marrow aspirates, or peripheral blood from six different
patientsand injected these into human bone chips, which had
been implanted in SCID-hu. H&E staining and immunohis-
tochemical staining with antihuman CD20 and cyclin D1
antibodies confirmed that patient’s MCL cells were able to
not only survive and propagate in the bone marrow
microenvironment of the human fetal bone chips, but also
similar to the human disease, migrate to the lymph nodes,
spleen, bone marrow, and gastrointestinal tract of host mice.
Treatment of MCL-bearing SCID-hu mice with atiprimod, a
novel antitumor compound against the protection of bone
marrow stromal cells, induced tumor regression [13].
As mentioned above, vascularization is crucial for the
development of tumors and targeting tumor vessels has
been shown to be effective in solid tumors of tumors.
Giatromanolaki et al. investigated vascular density and the
expression of hypoxia inducible factors (HIF) 1alpha and
2alpha, of vascular endothelial growth factor (VEGF), and
of the phosphorylated form of its receptor VEGFR2
(pVEGFR2/KDR) in a series of 146 B cell NHL and 48
normal lymph nodes. Vascular density was significantly
higher in the lymphoma compared to normal tissue, but
there was no association with expression of the examined
proteins. A significantly higher expression of HIF1alpha,
VEGF, and pVEGFR2/KDR) was recorded in DLBCL
compared to follicular lymphomas (FL). A strong statistical
association of pVEGFR2/KDR expression with high
HIF1alpha, HIF2alpha, and VEGF was noted in both
DLBCL and FL. HIF1alpha andHIF2alpha were linked
with VEGF expression, but no association between HIF1al-
pha and HIF2alpha was noted. It is concluded that the
VEGF/receptor pathway is active in more than half of
NHLs and particularly in DLBCL. The strong association
of HIFalphas with the expression of VEGF and pVEGFR2/
KDR found in the study provide strong evidence on the role
of HIFalphas in the activation of angiogenic and VEGF-
autocrine pathways that may be critical therapeutic targets
for HIF inhibitors or other antiangiogenic agents [14].
T cell lymphoma
In T cell lymphomas, one may commonly find many
eosinophilic granulocytes. Thielen et al. collected paraffin-
embedded specimens from 50 patients diagnosed with
peripheral T cell lymphomas, either unspecified (PTCL-U,
n=30) or angioimmunoblastic (AITL, n=20). Morpholog-
ical assessment for intratumoral eosinophilia and immuno-
histochemistry using specific antibodies directed against
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and IL-5-positive cases possessed significantly more eosi-
nophils. Our data indicate that IL-5 and TARC expression
highly correlate with eosinophilia in T cell lymphomas,
suggesting that these chemokines are involved in the
recruitment of eosinophils into the tumors [15].
Peripheral T cell lymphomas (PTCLs) are fatal in the
majority of patients and novel treatments, such as protein
tyrosine kinase (PTK) inhibition, are needed. The recent
finding of SYK/ITK translocations in rare PTCLs led us to
examine the expression of Syk PTK in 141 PTCLs. Syk
was positive by immunohistochemistry (IHC) in 133
PTCLs (94%), whereas normal T cells were negative.
Western blot on frozen tissue (n=6) and flow cytometry
on cell suspensions (n=4) correlated with IHC results in
paraffin. Additionally, Western blot demonstrated that Syk-
positive PTCLs show tyrosine (525/526) phosphorylation,
which is known to be required for Syk activation. FISH
showed no SYK/ITK translocation in 86 cases. Over-
expression of Syk, phosphorylation of its Y525/526
residues, and the availability of orally available Syk
inhibitors suggest that Syk merits further evaluation as a
candidate target for pharmacologic PTK inhibition in
patients with PTCL [16].
Bonzheim et al. investigated single nucleotide poly-
morphisms (SNPs) of the FAS and CTLA-4 genes in 94
peripheral T cell lymphomas since tumor cells of these
lymphoma fail to undergo apoptosis even in cases with the
phenotype of effector T cells and high expression of FAS
and CTLA-4 receptor molecules. Although allelic frequen-
cies of some FAS SNPs were enriched in AILT cases, none
of these occurred at a different frequency compared to
healthy individuals. Therefore, SNPs in these genes are not
associated with the apoptotic defect and autoimmune
phenomena in peripheral T cell lymphoma [17].
Anaplastic large cell lymphoma (ALCL), ALK1-positive,
is characterized by the constitutive activation of STAT3.
Bard et al. describe the existence of an autocrine stimulatory
loop involving interleukin-22 (IL-22) in ALCL by studying
cases and cell lines. The IL-22 receptor, a heterodimer
composed of IL-22R1 and IL-10R2, was expressed in all
ALK(+)ALCL cell lines and tumors examined. The expres-
sion of IL-22R1 in ALK(+)ALCL is aberrant, as this protein
is absent in benign lymphocytes. Although ALK(+)ALCL
cells produce endogenous IL-22, the addition of recombi-
nant IL-22 to ALK(+)ALCL cell lines significantly in-
creased STAT3 activation, cell proliferation, and colony
formation in soft agar. Nucleophosmin (NPM)-ALK, the
characteristic fusion gene oncoprotein expressed in ALK(+)
ALCL, directly contributes to the aberrant expression of IL-
22R1, as transfection of NPM-ALK in Jurkat cells induced
IL-22R1 expression and IL-22-mediated STAT3 activation
[18].
To identify highly recurrent genetic alterations typical of
Sézary syndrome (Sz) high-resolution array-based compar-
ative genomic hybridization was done on malignant T cells
from 20 patients. Minimal common regions with copy
number alteration occurring in at least 35% of patients
harbored 15 bona fide oncogenes and three tumor suppres-
sor genes. Based on the function of the identified
oncogenes and tumor suppressor genes, at least three
molecular mechanisms are relevant in the pathogenesis of
Sz. First, gain of cMYC and loss of cMYC antagonists
(MXI1 and MNT) were observed in 75% and 40% to 55%
of patients, respectively, which were frequently associated
with deregulated gene expression. Second, a region
containing TP53 and genome maintenance genes (RPA1/
HIC1) was lost in the majority of patients. Third, the
interleukin-2 (IL-2) pathway was affected by gain of
STAT3/STAT5 and IL-2 (receptor) genes in 75% and
30%, respectively, and loss of TCF8 and DUSP5 in at least
45% of patients. [19].
The cutaneous CD30-positive lymphoproliferations en-
compass a spectrum of disorders that share histological and
phenotypic similarities but differ markedly in clinical
behavior. Gjeerdrum et al. studied the expression of FoxP3
as a marker of Tregs in skin biopsies from lymphomatoid
papulosis (LyP) (n=14), primary cutaneous anaplastic large
cells lymphoma (C-ALCL) (n=13), and systemic anaplastic
large cells lymphoma (S-ALCL) with (n=9) or without (n=
6) ALK expression. Only one case of C-ALCL was positive
for FoxP3, and in three cases, occasional tumor cells were
positive. All biopsies contained tumor-infiltrating FOXP3-
positive Tregs, however, with significant higher numbers in
ALK-negative S-ALCL and LyP than in C-ALCL and S-
ALCL positive for ALK [20].
Epidemiology of lymphoma
Increasingly, reports from different regions in the world
indicate the great variation in the epidemiology of cancer
and many important lessons can be learned from that. Also,
it is becoming clear that survival of patients with a variety
of tumor types is really improving.
HL shows a bimodal distribution with a first peak in
developing countries during childhood. The causative role
and prognostic significance of EBV association in patients
with HL is controversial. In two Latin-American pediatric
HL series, EBV-encoded RNAs in situ hybridization and
latent membrane protein 1 immunohistochemistry on HL
biopsies from 176 pediatric patients was positive in 52% of
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cellularity subtype but was not related to survival. The
results do not support EBV association stated for pediatric
HL in developing countries [21].
NHL is the most common hematologic malignant
neoplasm in adults. The most recent trends in survival
among adults diagnosed as having NHL on the population
level in the US show that, overall, 5-year relative survival
increased from 50.4% to 66.8% and 10-year relative survival
increased from 39.4% to 56.3% between 1990–1992 and
2002–2004. Improvements were most pronounced in
patients younger than 45 years (+26.8 and +27.1 percentage
points for 5- and 10-year survival, respectively), but
improvements were seen in all age groups, in both sexes, in
bothnodalandextranodaldisease,andinbothlow-gradeand
high-grade disease. Improvements in prognosis were less in
black patients than in white patients, especially in younger
black patients. Changes in treatment of the disease and a
decrease in the number of human immunodeficiency virus-
related NHL cases attributable to highly active antiretroviral
therapy are probably primarily responsible for these
improvements [22].
The incidence, risk factors, and endoscopic presentation
of gastrointestinal non-Hodgkin’s lymphoma (GI NHL) was
described in a large predominantly urban adult population
sample by Andrews et al. Data over a 5-year period (1999–
2003) from Calgary, Canada were collected and supple-
mented with data population-based HIV database (1985–
2004). The 56 GI NHL cases imply an annual incidence of
1.73 per 100,000, the majority being DLBCL (54%),
followed by extranodal marginal zone lymphoma (MALT
lymphoma; 29%). Increasing age, history of kidney trans-
plant, and Helicobacter pylori positivity in MALT lympho-
ma were identified as risk factors. Within the HIV-positive
population, a highly significant drop in GI NHL was seen
over time with an incidence of 3.86 per 1,000 patient-years
in 1985–1989 compared to zero cases in 2000–2004,
despite a greater prevalence of HIV disease [23].
Mwakigonja et al. were able to study 176 lymphoma
cases from Tanzania, collected from 1996–2001. The
proportion of lymphomas out of all diagnosed tumors was
4.2% (176/4,200) comprising 77.8% NHL including 19.3%
Burkitt’s (BL) and 22.2% HL and 23.7% of tested sera from
these patients were HIV-positive. In this short period of
time, malignant lymphomas increased significantly, pre-
dominantly among the young, HIV-infected, and AIDS
patients [24].
The most common NHLs in Uganda are neoplasms of B
cell derivation and 129 such cases were classified as BL (95
cases), DLBCL (19 cases), MCL (four cases), and B cell
lymphoblastic lymphoma (one case). In BL, a homoge-
neous phenotype (CD10(+), BCL6(+), Bcl-2(−), MUM1/
IRF4−, and Ki-67 approximately 100%) and a stable EBV
integration were found. A distinctive and unusual feature
was the frequent plasma cellular differentiation, along with
the positivity for CD30 and CD138 (recorded in 35 and 43
cases, respectively) [25].
EBV-associated lymphoproliferations are common in
East Asia. Cho et al. determined the spectrum of EBV-
positive lymphoproliferative diseases (LPD) and relation-
ships between these diseases in Korea. The EBV status and
clinicopathology of 764 patients, including acute EBV-
associated hemophagocytic lymphohistiocytosis (EBV-
HLH), chronic active EBV (CAEBV) infections, B-LPD
arising in chronic latent EBV infection, T and natural killer
(NK) cell NHL, B-NHLs, and HL were analyzed. T or NK
cell NHLs were the most common forms of EBV-positive
NHLs (107/167, 64%); among these, nasal type NK/T cell
lymphomas were the most common (89/107, 83%).
According to age, BL was the most common in early
childhood; in teenagers, chronic (active) EBV infection-
associated LPD was the most common type. The incidence
of NK/T cell lymphoma began to increase from the twenties
and formed the major type of EBV-associated tumor
throughout life. DLBCL formed the major type in the
elderly. In conclusion, primary infections in early childhood
are complicated by the development of CAEBV infections
that are main predisposing factors for EBV-associated T or
NK cell malignancies in young adults. In old patients,
decreased immunity associated with old age and environ-
mental cofactors may provoke the development of periph-
eral T cell lymphoma, unspecified, and DLBCL [26].
Sjo et al. analyzed the epidemiology of the rare
ophthalmic lymphoma in Denmark during the period 1980
to 2005. A total of 228 patients with a histologically
verified diagnosis of ophthalmic lymphoma were included.
There was an equal distribution of men and women. The
most frequent lymphoma subtype was extranodal marginal
zone B cell lymphoma (MALT lymphoma, 55.5%) and
most cases were located in the orbit (56.8%). High-grade
lymphoma subtypes were found more frequently in men
than in women. Incidence rates were highly dependent of
patient age. For all ages, a statistically significant annual
average increase of 3.4% during the 26-year period was
found. This was primarily due to a rise in incidence of
MALT lymphoma [27].
Defining entities
Soon, the new WHO classification will become available. It
is increasingly difficult to find a balance between lumping
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cases becomes available. At the same time, for some
entities, it remains difficult to classify them reliably. It is,
however, difficult to make choices on which new tools need
to be implemented in routine practice.
Hodgkin lymphoma
Programmed death 1 (PD-1) is a lymphoid receptor that
negatively regulates immune responses and is a marker of
follicular T cells that forms rosettes around the neoplastic
cells in NLPHL. Nam-Cha et al. analyzed the diagnostic
value of PD-1 staining in 152 cases of various types of HL
and T cell-rich diffuse large B cell lymphoma (TRBCL).
Results show that PD-1 (NAT-105) is a marker not only of
follicular T cell rosettes in NLPHL, but also of a subset of
lymphocyte-rich cHL and is absent in TRBCL. The
presence of PD-1-positive T cell rosettes, therefore, seems
to be an additional useful feature in the sometimes difficult
differential diagnosis of NLPHL and T/HRBCL; in border-
line cases (probably discussed in Bordeaux!), PD-1 positive
rosettes are present, so these cases more likely represent
NLPHL [28]. PD-1 expression was also reported in some
T cell NHL subtypes. Xerri et al. describe the expression
profile of PD-1 and its ligands (PD-L1 and PD-L2) in 161
lymphoma tissue and 11 blood samples of B-NHLs. In
reactive lymph nodes, PD-1 was mainly expressed in
follicular T cells. In B-NHLs, PD-1 was mainly expressed
in reactive T cells as well, but expression was also noted
in neoplastic B cells from small lymphocytic lymphoma
(SLL, 12/13), grade III follicular lymphoma (3/3), and
DLBL (2/25). In contrast, neoplastic B cells from MCL (0/
11), marginal zone lymphoma (0/12), BL (0/3), and grade
1 to 2 follicular lymphoma (0/40) were PD-1 negative.
PD-L1 and PD-L2 were negative in small B cell
lymphomas, including B-SLL. Flow cytometry showed
that blood cells from chronic lymphocytic leukemia (B-
CLL) also displayed PD-1 expression, which could be
increased by CD40 stimulation. PD-1 expression in T-
NHLs was restricted to the angioimmunoblastic subtype
(8/8). These results show that PD-1 expression among B-
NHLs is mainly associated with SLL/CLL and is influ-
enced by the activation of the CD40/CD40L pathway.
Because the anti-PD-1.6.4 antibody works on paraffin
sections, it represents a useful tool to differentiate SLL/
CLL from other small B cell lymphomas [29].
B cell lymphomas
The WHO classification defines entities by morphology,
immunophenotype, genetics, and clinical features. An
important example of the latter is age, and it is increasingly
recognized that pediatric lymphomas might be different
from adult cases, even when they are the same subtype.
Klapper et al. contradict this by analyzing 65 cases of
mature aggressive B cell NHL from patients up to 18 years
of age and compared to results to those of 182 adult
patients. Gene expression profiling reclassified 31% of
morphologically defined DLBCLs as molecular Burkitt
lymphoma (mBL), but the subgroups obtained by molecu-
lar reclassification did not show any difference in outcome.
No differences were detectable between pediatric and adult
mBL with regard to gene expression or chromosomal
imbalances. They conclude that based on molecular
profiling mBL is a molecularly homogeneous disease
across children and adults [30]. The important question
remains whether molecular profiling will override the
present criteria in classifying lymphomas of children; at
least in this study, prognostic information based on standard
diagnosis, i.e., DLBCL vs. BL gets lost after classifying
according expression profiling.
As written in the previous review of the literature,
follicular lymphoma in Japan is genetically different from
cases in the west. Karube et al. studied 100 BCL2
rearrangement negative follicular lymphomas and identified
four subgroups. Group I: BCL6 gene rearrangement (n=
41); group II: BCL6 gene amplification/3q27 gain (n=30);
group III: the absence of both (n=23); and group IV: the
presence of both (n=6). Group II showed higher grade
morphology (grade 3a/b, 93%), higher bcl2 and MUM1
expression (73 and 57%, respectively), and more frequent
combination with BCL2 gene amplification/18q21 gain
(90%) than the other groups [31]. Further studies are
needed on the relevance of these findings.
In the Kiel classification, follicular centroblastic lym-
phoma was separated from follicular centroblastic centro-
cytic lymphoma and put in the category of centroblastic
lymphoma. Piccaluga et al. showed that this separation has
indeed a molecular basis, although both types belong to the
same category and are distinct from other large cell
lymphomas. Using expression profiling of 43 follicular
lymphomas, 50 B cell NHLs of different type, and 20
samples of normal B lymphocytes, it became clear that the
molecular profile of follicular lymphoma is intimately
related to that of normal germinal center B cells, irrespec-
tive of the histological grade. Furthermore, follicular
lymphoma has a relatively homogeneous gene expression
profile that is distinct from that of other B cell NHL and
does not include discrete molecular subgroups. However,
by further clustering, grade I–IIIa tumors tend to cluster
together, while grade IIIb follicular lymphoma constitutes a
distinct subgroup whose molecular signature is closer to
that of the remaining follicular lymphomas than to that of
DLBCL of the germinal center B cell type [32].
Martinez et al. studied the expression of interferon
regulatory factor (IRF) 8 in reactive lymphoid tissues and
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a variety of B cell developmental stages. Although IRF8 was
detectable in most reactive B cells, its expression levels
differed with developmental stage. Germinal center B cells
containedthehighestlevelsofIRF8withlowerlevelsseenin
mantle and marginal zone B cells and none in plasma cells.
IRF8 was coexpressed with PAX-5, Pu.1, and BCL 6 and
similar to BCL6, was absent from the small population of
IRF4-positive germinal center B cells thought to be
committed to postgerminal center developmental programs.
Similarly, IRF8 was most strongly expressed in lymphomas
of germinal center origin with lower levels present in MCL,
CLL, and marginal zone lymphomas, and no expression
observed in plasmacytic/plasmablastic neoplasms. The re-
ciprocal expression pattern with IRF4 in reactive tissues was
generally maintained in lymphomas with some exceptions.
These results provide a new diagnostic marker helpful in
distinguishing B cell NHL subtypes [33]. Obviously, it will
be important to know whether this marker may separate
activated from germinal center DLBCL (see below, prog-
nostic factors). Baecklund et al. describe another new
germinal center marker, human germinal center-associated
lymphoma protein (HGAL), in DLBCL of patients with
rheumatoid arthritis. Of 111 cases, 38 (34%) DLBCL were
HGAL-positive and showed less disseminated disease and a
tendency toward improved overall survival compared to
HGAL-negative cases. This supports that a majority of RA-
DLBCL are of non-GC origin, indicating a specific role for
activated peripheral B cells in the pathogenesis of RA-
DLBCL [34].
The chemokines (CKs) CXCL13, CCL21, and CXCL12
are known to play differential roles in the organization of
the lymphoid tissues and the development of lymphoid
malignancies. Barone et al. showed that, within salivary
glands with lymphoepithelial sialadenitis (LESA) and
MALT lymphoma, the lymphoid CKs CXCL13 and
CCL21 are selectively associated with areas of reactive
lymphoid proliferation, whereas no significant expression
of these molecules was detected in the malignant lymphoid
aggregate. Conversely, CXCL12 was observed predomi-
nantly in infiltrated ducts and malignant B cells. Accord-
ingly, CXCL13 and CCL21 transcript levels were
significantly increased in LESA samples while CXCL12
levels were increased in MALT lymphoma and isolated
tumor cells. Low levels of CK receptors were detected on
lymphoma-extracted lymphocytes, suggesting downregula-
tion in the abundance of ligands [35]. These findings may
assist in the sometimes difficult distinction of reactive vs.
malignant infiltrates in salivary glands, especially those of
patents with Sögrens syndrome.
Nakamura et al. investigated the incidence and clinical
significance of lymphoma-associated chromosomal trans-
locations, particularly those involving the immunoglobulin
heavy chain (IGH) gene locus, in a large series of gastric
DLBCL (141 cases of primary gastric DLBCL [58 with
MALT lymphoma and 83 without MALT lymphoma])
using FISH. Translocations involving IGH were detected
in 36 (32%) of 111 cases; their partner genes included
BCL6 (n=10), c-myc (n= 5 ) ,a n dF O X P 1( n=3) but
remained unknown in the remaining 18 cases. t(14;18)/
IGH-BCL2, t(14;18)/IGH-MALT1, and t(1;14)/BCL10-
IGH were not detected in any case. t(11;18)/API2-MALT1
was detected in none of the cases, except for one case of
DLBCL with MALT lymphoma, which showed positive
signals only in MALT lymphoma cells. IGH-involved
translocation was associated with younger age but not with
any other clinicopathologic factors including GCB or non-
GCB immunophenotypes. Cox multivariate analysis
revealed that IGH-involved translocation, in addition to
younger age and early stage, was an independent prognostic
factor for better overall and event free survival [36].
The role of microRNAs is becoming increasingly clear.
SeveralmiRNAshavebeenreportedtobeassociatedwithIgH
mutation and ZAP-70 expression status in blood samples of B
cell chronic lymphocytic leukemia/small lymphocytic lym-
phoma (B-CLL/SLL). Wang et al. collected and analyzed 33
lymph nodes and 37 blood CLL samples and analyzed IgH
mutationstatus,ZAP-70expressionstatusandexpressionof
15 miRNAs. Sixty-three percent of the lymph node cases
contained mutated IgH genes and 49% of the lymph node
cases were ZAP-70-positive, and a significant correlation
was observed between ZAP-70 expression and IgH muta-
tion status. Of the blood CLL samples, 49% contained
mutated IgH sequences. The miRNA expression pattern in
CLL lymph node and blood samples was very similar. Three
of 15 miRNAs (miR-16, miR-21, and miR-150) showed a
high expression level in both blood and lymph node
samples. No difference was observed between ZAP-70-
positive and ZAP-70-negative and between IgH-mutated
and unmutated cases. No correlation was found between
miR-15a and miR-16 expression levels and 13q14 deletion
in the blood CLL samples [37].
In a series of 63 primary DLBCLs of bone collected
from centers in France and Brazil, a substantial number of
cases had a rearrangement of BCL2 (9/32) or c-myc (n=3),
whereas the PAX5, BCL6, BCL1 cyclin D1, and ALK
genes were in germline configuration. The majority of the
cases with rearrangements were of the GC phenotype.
These results, associated with the lack of BCL6 rearrange-
ment, suggest that bone DLBCL represents a specific group
within extranodal B cell lymphomas [38].
Primary lymphomas of the CNS (PCNSLs) show
molecular features of the late germinal center exit B cell
phenotype and are impaired in their terminal differentiation
as indicated by a lack of immunoglobulin class switching.
Because the positive regulatory domain I protein with ZNF
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nal B cell differentiation into plasma cells, Courts et al.
investigated a series of 21 PCNSLs for the presence of
mutations in the PRDM1 gene and found deleterious
mutations in four of 21 (19%) PCNSLs. They conclude
that, similar to systemic DLBCLs, PRDM1 may be a tumor
suppressor in some PCNSL and contribute to lymphoma-
genesis by impairing terminal differentiation [39]. Maybe
as important, this finding goes against the notion that this
PCNSL is a distinct entity.
Plasmablastic lymphoma (PBL) and multiple myeloma
(MM) are B cell-derived malignancies that share many
morphologic and immunophenotypic traits, making the
differential diagnosis particularly complicated. Damasi et
al., after demonstrating that peroxiredoxin I (PrdxI) is
expressed in plasma cells but not in B lymphocytes,
analyzed eight cases of PBL and nine of MM by
immunohistochemistry. The results show that that PrdxI
expression is closely connected with the immunoglobulin
production capacity of the cells, which means high in MM,
but absent in PBL cases, except one, wherein few cells
were stained. PrdxI, therefore, could be considered an
additional plasma cell functional marker and thus may
serve as a marker for MM [40].
T cell lymphomas
Many years after his retirement, Prof. Lennert remains
active in the field of lymphoma diagnosis. In a recent paper
from the Kiel group, the importance of morphology is
stressed in this era of expression profiling. Reevaluating a
historical series of 17 lymphomas, diagnosed as lympho-
histiocytic lymphoma according to the criteria of the Kiel
classification with the presence of large purple macro-
phages (LPM) as the decisive finding for diagnosing this
lymphoma subtype, the relation to the lymphohistiocytic
variant of ALCL according to the WHO classification was
studied. All cases in the cohort matched the criteria of
ALCL according to the WHO classification; in 30% of the
cases, the total amount of macrophages did not exceed the
number of CD30-positive tumor cells. The results indicate
that the presence of LPM might be helpful to identify this
subgroup of ALCL. Because the distinction of morpholog-
ical subtypes of ALCL is of clinical relevance, improved
criteria for subtyping ALCL are urgently needed and might
include the presence LPM as one such criterion [41].
Completely opposite to the conclusions by Verbeek et al.
(see previous review of the literature in issue 1), celiac
disease (CD) is characterized by villous atrophy and an
increase in intraepithelial lymphocytes (IEL), of which the
IEL usually exhibit a suppressor/cytotoxic phenotype (CD3
and CD8) and display a polyclonal profile for T cell
receptor (TCR) rearrangement as opposed to the mono-
clonality of refractory CD (RCD) with CD8 IEL. A
complication of CD is the loss of response to a gluten-
free diet called RCD that may progress to an enteropathy-
associated T cell lymphoma. De Mascarel et al. studied 20
uncomplicated CD and 23 complicated CD (19 RCD and
four diagnosed at the same time as enteropathy-associated
T cell lymphoma). In complicated CD, the IEL phenotype
was CD8 in nine cases and CD8 in 14 cases. In 100% of
cases, IEL showed a monoclonal TCR rearrangement. All
the nine CD8 complicated CD exhibited a monoclonal TCR
rearrangement and three of them were associated with a T
cell lymphoma (two at the same time as CD and one after
43 months follow-up) and bore the same monoclonal
rearrangement in IEL and in lymphoma. Interestingly, the
13 cases (100%) of CD with a CD8 phenotype were also
found monoclonal and two of them were associated with a
T cell lymphoma diagnosed at the same time as CD and
exhibiting the same rearrangement in IEL and in lympho-
ma. An aberrant CD3 CD8 IEL phenotype is a good
criterion for RCD diagnosis. However, cases with a normal
CD3 CD8 IEL phenotype may correspond to RCD. In such
cases, molecular analysis of TCR-gamma genes is a useful
method for identifying cases with RCD [42]. It is unclear
why the results of the two studies are so divergent.
Cutaneous lymphomas
The series of studies of the Willemze group on the
classification of cutaneous lymphomas have firmly defined
the existence of two distinct primary cutaneous large B cell
lymphomas: primary cutaneous follicle center lymphoma
(PCFCL), characterized by an excellent prognosis, and
primary cutaneous large B cell lymphoma, leg type
(PCLBCL leg type) with an unfavorable prognosis. Now
van Galen et al. investigated 21 cases with expression
profiling and conclude that the results suggest that the
clinically favorable PCFCLs are characterized by a rela-
tively intense cellular cytotoxic immune response and that
PCLBCL leg types are characterized by constitutive
activation of the intrinsic mediated apoptosis pathway with
concomitant downstream inhibition of this apoptosis path-
way [43].
New entities/subtypes
DLBCL usually proliferates effacing lymph follicles. In
occasional cases, tumor cells show an interfollicular pattern
of proliferation preserving lymph follicles. Yamauchi et al.
showed that DLBCL with an interfollicular pattern of
proliferation has distinct clinical and pathological findings
compared to ordinary DLBCL. Twelve cases of DLBCL
with an interfollicular pattern of proliferation [interfollicular
152 J Hematopathol (2008) 1:145–160group (IF)] were compared to 30 cases of DLBCL with
ordinary morphology [control group (CG)]. IF showed a
significantly lower lactate dehydrogenase level and Inter-
national Prognostic Index scores and the frequency of
localized disease were higher than that in CG. Immunohis-
tochemically, the majority (11 of 12) of IF cases showed a
nongerminal center B cell phenotype which was higher than
that in CG [44].
Most cases of intravascular large cell lymphoma have a
B cell phenotype, but rare T cell and NK cell variants have
been reported. Four patients (M/F=3:1; age range, 63 to
87 years; median age, 65 years) with intravascular large
NK/T cell lymphoma were described by Cerroni et al. The
skin was the site of presentation in all patients (leg, one
case; trunk, one case; trunk and extremities, two cases).
Two patients had lesions confined to the skin; in one case,
concomitant involvement of the brain was detected, and in
one case, no further studies were carried out. Immunohis-
tology showed positivity for cytotoxic markers in three of
four cases. One case had an NK phenotype similar to NK/T
cell lymphoma, nasal type, whereas the other cases could not
be precisely classified into specific categories. One of these
cases was negative for cytotoxic markers and was positive
only for CD2 and CD3. Association with EBV was
demonstrated in two cases by in situ hybridization, whereas
one case was negative. All the patients had aggressive disease
and died between 2 weeks and 7 months from presentation.
Intravascular large NK/T cell lymphoma is a rare, aggressive
lymphoma with variable phenotypic features, frequent ex-
pression of cytotoxic proteins, true NK cell phenotype and
association with EBV infection, and common presentation in
the skin [45].
Nowadays, many reports deal with the new syndrome/
entity IgG4-related sclerosing disease, which is a recently
recognized inflammatory lesion frequently involving the
pancreas, submandibular gland, lacrimal gland, and lymph
node. Cheuk et al. describe the hematopathological features
in this syndrome in two papers. The first one deals with the
morphologic features of the enlarged regional (n=3) and
nonregional lymph nodes (n=3) in patients. The histologic
features of the lymph nodes could be categorized into three
patterns: Castleman disease-like, follicular hyperplasia, and
interfollicular expansion by immunoblasts and plasma cells.
The percentage of IgG4+/IgG+ plasma cells was markedly
elevated (mean 62% vs. 9.9% in 54 control lymph nodes
comprising a wide variety of reactive conditions). Six cases
of primary lymphadenopathy were characterized by in-
creased IgG4+/IgG+ plasma cells (mean 58%). These cases
share many clinical and pathologic similarities with IgG4-
related sclerosing disease. In fact, two of these patients
developed lymphoplasmacytic sclerosing cholangitis or
lacrimal and submandibular gland involvement during the
clinical course. These cases, therefore, probably represent
primary lymph node manifestation of the disease. The
importance of recognition of the lymphadenopathic form of
IgG4-related sclerosing disease lies in the remarkable
response to steroid therapy, and the potential of mistaking
the disease for lymphoma either clinically or histologically
[46]. The second paper describes three cases of ocular
adnexal lymphoma arising in IgG4-related chronic scleros-
ing dacryoadenitis. The patients presented with bilateral or
unilateral ocular adnexal mass usually present for many
years. One patient also had asymptomatic diffuse lymph-
adenopathy. Two patients had biopsy-proven IgG4-related
chronic sclerosing dacryoadenitis before the current pre-
sentation, and one had systemic involvement by IgG4-
related sclerosing disease as evidenced by increased IgG4+
cells in a prior nasopharyngeal biopsy. Two cases showed
features of extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue type (one with large cell
transformation) and one follicular lymphoma. Presently,
the mechanism and impact of the findings remain unclear
[47]. Kojima et al. describe IgG4 elevated serum levels in
one of their three patients with reactive follicular hyperpla-
sia and prominent interfollicular plasmacytosis in regional
lymph nodes of their Küttner’s tumor. The polytypic nature
of plasma cells was demonstrated by immunohistochemistry.
There were numerous IgG-positive plasma cells with
scattered IgA-positive or IgM-positive plasma cells. IgG4-
positive cells comprised 25% to 40% of IgG-positive
plasma cells. These three cases indicated that regional
lymph node of Küttner’s tumor may show reactive
follicular hyperplasia and prominent interfollicular plasma-
cytosis and should be differentiated from various benign
and malignant lymphoproliferative disorders including
systemic rheumatic disease, plasma cell type of Castleman
disease, and lymph node involvement of marginal B cell
lymphoma of the MALT type showing prominent plasma
cell differentiation [48].
Pitfalls in lymphoma diagnosis
Farris et al. studied 11 cases of rectal tonsil (RT), a
localized reactive proliferation of lymphoid tissue occurring
in the rectum, which, since it is not well-known to many
pathologists, can cause diagnostic difficulty, and awareness
of this entity can prevent a misdiagnosis of lymphoma. The
patients (six males and five females) were middle-aged
adults, except for one case affecting a young boy (age
range, 1 to 62 years; mean, 49 years). All presented with
either rectal bleeding or abdominal pain or had the lesion
found on routine screening. Histologically, all cases were
composed of a lymphoid proliferation involving the lamina
propria or submucosa. Lymphoid follicles could be identi-
fied in all cases, although some were difficult to appreciate
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epithelial lymphocytes were present in nine cases, and five
cases showed nondestructive lymphoepithelial lesions.
During a mean follow-up of 5.8 years, none showed a
recurrence or developed lymphoma. Familiarity with the
range of histologic features characteristic of the RT is
critical in avoiding misinterpretation as lymphoma [49].
Flow cytometric analysis of CD23 expression in CD5-
positive B cells is a widely applied method in the differential
diagnosis of CLL and MCL. According to the most accepted
criteria, the leukemic cell population is CD19/CD5/CD23
triple positive in CLL but CD23-negative in MCL. Recently,
several groups have reported CD23-positive MCL cases;
however, these studies mostly analyzed only CD23 positiv-
ity but not intensity. Barna et al. compared 26 cases of MCL
and 84 cases of CLL using flow cytometric analysis and
found that high values of CD23 positivity (>92.5%) and/or
high fluorescence intensity (>44.5 mean fluorescence inten-
sity [MFI]) of CD23 are related to CLL, whereas low CD23
positivity (<30%) is related to MCL. However, cases with
intermediate CD23 positivity (between 30% and 92.5%) and
lower intensity (<44.5 MFI) can either belong to CLL or
MCL. In these cases, additional tests such as FISH analysis
of the translocation t(11;14) or immunohistochemical detec-
tion of cyclin D1 overexpression are required to differentiate
CLL from MCL [50].
The morphologic findings of different types of marginal
zone B cell lymphoma (MZL) involving the bone marrow
(BM), including 18 splenic (SMZL), six extranodal (MALT
lymphoma), and six nodal cases were compared by Inamdar
et al. The median percentage of BM involvement was 15%,
and multiple overlapping patterns of infiltration were
observed in all MZL types. The most frequent patterns
were nodular (87%) and interstitial (63%). A focal
sinusoidal pattern of involvement was found in one third
of SMZLs and rarely in MALT lymphoma. Germinal
centers (GCs) were uncommon in routinely stained BM
biopsy sections and were observed only in SMZL.
However, antibodies specific for CD21 and CD23 high-
lighted follicular dendritic cells in most MZLs of all types.
MZLs cannot be distinguished from each other by
examining BM sections alone. However, a sinusoidal
pattern or presence of GCs is suggestive of SMZL [51].
A rare but relevant pitfall was described by Holanda et
al., namely, a primary gastric T cell lymphoma morpholog-
ically similar to the gastric marginal zone B cell lymphoma
of MALT. Careful interpretation of the immunohistochem-
istry with additional clonality testing will solve such cases
[52].
Normal precursor B cells or hematogones share mor-
phologic and immunophenotypic similarities with lympho-
blasts of precursor B lymphoblastic leukemia. The numbers
are often increased and difficult to distinguish in many
patients following chemotherapy for precursor B lympho-
blastic leukemia. The purpose of the study of Hurford et al.
was to establish a method for differentiating hematogones
from lymphoblasts by evaluating the immunofluorescence
pattern of nuclear terminal deoxynucleotidyl transferase
(TdT) staining in 29 cases of TdT+ acute leukemia and 20
cases with increased numbers of hematogones. All 29 cases
of TdT+ acute leukemia demonstrated a finely granular
pattern of TdT immunofluorescence that was uniformly
distributed in the nucleus, whereas all 20 cases with
increased hematogones demonstrated a coarsely granular or
speckled pattern of TdT immunofluorescence, which often
intensely aligns the nuclear membrane. The nuclear pattern
of immunofluorescence using antibodies to TdT is an
effective method for distinguishing hematogones from
leukemic blasts [53].
Large CD30-positive cells are the hallmark of cutaneous
CD30-positive lymphoproliferative disease, but are not
specific for that diagnosis. Werner et al. studied 28 cases
of benign cutaneous infiltrates, mainly drug- or virus-
induced lesions, and found clusters of such cells with Golgi
staining of the CD30 in most of these. It is, therefore,
crucial that clinical and pathological data are evaluated with
care before the diagnosis of lymphomatoid papulosis or
large cell anaplastic lymphoma of the skin, the two ends of
the spectrum of cutaneous CD30-positive lymphoprolifer-
ative disease, is made [54].
Treatment of patients before a biopsy is taken is
sometimes necessary, but may influence to morphology
making a diagnosis difficult. Porter et al. evaluated their
experience in 109 patients with primary central nervous
system lymphoma (PCNSL). Sixty-eight (63.6%) patients
received corticosteroids before diagnosis. Thirteen patients
(of 109; 12%) had undergone repeat brain biopsy to
confirm PCNSL. These included eight (of 68) patients
who had received corticosteroids (12%), and five (of 39)
who had not (13%) (p=1.0). Therefore, the majority of
PCNSL patients who received corticosteroids before diag-
nosis could be reliably diagnosed on the first biopsy and
did not require second biopsy for diagnosis [55].
Diagnosing two different diseases in one patient is
always difficult. The coexistence of T cell large granular
lymphocyte leukemia (T-LGL) with B cell abnormalities
has been described previously. Viny et al. performed a
systematic analysis to determine the frequency of this
coassociation on 63 T-LGL and identified coexisting B cell
dyscrasias in 17 T-LGL patients (27% of total), of whom 12
had monoclonal gammopathy of unknown significance
(MGUS) (19%) and five had CLL (8%). The presence of
both MGUS and CLL was found in two patients (3%) and
follicular lymphoma was identified with MGUS in another
T-LGL patient (2%). Additionally, polyclonal hypergam-
maglobulinemia or hypogammaglobulinemia was found in
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frequency of B cell abnormalities in T-LGL leukemia to
43%. The coassociation of B cell pathology with T-LGL
suggests that either a common antigen drives clonal B and
T cells or that humoral malignancy could serve as the
stimulus for lymphocyte expansion representing an overac-
tive antitumor surveillance [56].
Aberrant expression of cytokeratins (CK) is known to
occasionally occur in malignant lymphomas. The monoclo-
nal mouse antihuman CK cocktail CK22 recognizes keratin
polypeptides with a wide range of molecular weights and can
beappliedindiagnosticpanelsfortumorsofunknownorigin.
Using tissue microarray technology, 1,059 lymphoma and
acute leukemia cases, covering the most common disease
entities, were tested for aberrant CK expression using CK22.
Intotal,866ofthearrayedcaseswereevaluable(80%)and13
positive cases (1.5%) were found: one out of 230 HL (0.4%),
one plasma cell myeloma, two out of 326 DLBCLs (0.6%),
five out of 18 MCL (26%), three out of 70 SLL/CLL (4%),
one out of 27 peripheral Tcell lymphomas, and not otherwise
specified (4%). Immunostaining was finely granular in most
cases, and the total amount of positively staining cells
exceeded 10% only in the cases of HL and plasmocytoma.
All CK22-positive cases, except for one MCL, expressed the
specific simple epithelial CK8 but not the basal/stratified
epithelial CK5/6. Aberrant CK expression can be encoun-
tered in a small subset of otherwise characteristic B and Tcell
lymphomas, but not in acute leukemias [57].
Prognostic factors in lymphoma
Adult T cell acute lymphoblastic leukemia (T-ALL) con-
tinues to represent an unfavorable disease. Molecularly
based treatment stratifications could help improve outcome.
The prognostic impact of HOX11 and HOX11L2 expres-
sion has been an area of controversy. In 286 adult T-ALL
patients enrolled into the German Multicenter ALL therapy
protocols, high HOX11 expression and HOX11L2 expres-
sion were predominantly seen in thymic T-ALL. In a
multivariate analysis, HOX11L2 expression proved to be an
independent adverse risk factor for relapse-free and overall
survival. HOX11 expression was found to have a favorable
impact on relapse-free but not overall survival. Thus,
patients with aberrant HOX11L2 expression should be
considered early as candidates for intensified treatment
regimes [58].
In 67 patients with extranodal marginal zone lymphoma
of the stomach, Yamamoto et al. analyzed factors that
predict tumor regression upon H. pylori eradication. In 28
(42%) of the cases, the tumor cells expressed CXCR3, a
chemokine receptor involved in B cell homing. This
expression was related to unresponsiveness for eradication
of H. pylori, and although CXCR3 expression is correlated
to t(11;18), a known marker for unresponsiveness, it
remained its prognostic impact in a multivariate model [59].
MCL is a very popular lymphoma for research.
Hartmann et al. studied expression levels of 33 genes by
q-RTPCR in 73 patients with MCL and were able to create
a profile that gave superior prognostic information com-
pared to Ki67 staining, a known strong prognosticator. Five
genes from this profile were studied in paraffin samples of
54 cases and the findings were comparable [60]. It will,
however, be difficult to translate these results in clinical
practice as is exemplified by the situation in DLBCL where
profiling about a decade ago has resulted in the recognition
of two subgroups, activated and germinal center types,
which are prognostically very different. Many studies have
used immunohistochemistry to recognize these groups, but
only to limited success. Uccella et al. used the most
common approach with CD10, Bcl-2, BCL6, and MUM1
antibodies in 71 patients and could not find prognostic
relevance, although BCL6 expression as single marker was
[61]. Likewise, Katzenberger et al. analyzed cytogenetic
alterations in 223 cases of MCL by FISH and/or classical
cytogenetics and correlated the results with Ki67 expression
and survival. Complex aberrations are associated with high
proliferation and poor prognosis. A comprehensive analysis
of biological features including genetic alterations in MCL
by hierarchical clustering resulted in the delineation of four
tumor subgroups differing with respect to their genetic
constitution and suggesting different transformation or
progression pathways. Moreover, in one of the groups
identified, a more indolent clinical behavior was associated
with few secondary aberrations and fewer known high-risk
chromosomal aberrations [62]. More straightforward is the
study by Zanetto et al. who analyzed 17 samples from 14
patients with MCL with aberrant expression of CD10. Five
of the cases had blastoid morphology, also five were CD5
negative and BCL6 was expressed by another five, showing
that the diagnosis of MCL requires knowledge of the full
spectrum of the disease [63].
In the large series of studies dealing with p53, Young et
al. adds data that show that the 102 cases with p53 mutation
out of 477 patients with DLBCL have a significantly worse
prognosis. They were able to show that the location of the
mutation affects the prognostic impact. Multivariate analy-
sis confirmed that the International Prognostic Index and
mutations in the DNA-binding domains of p53 were
independent predictors. TP53 mutations also stratified
patients with germinal center B cell-like DLBCL, but not
nongerminal center B cell-like DLBCL, into molecularly
distinct subsets with different survivals [64].
It is now broadly accepted that DLBCL can be
subdivided into the prognostically significant groups
germinal center B cell-like (GCB) and activated B cell-like
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immunostained 163 de novo DLBCLs from Chinese
patients with CD20, CD10, BCL6, MUM1, CD138, Bcl-
2, Ki-67, cyclin D3, geminin, and P27(Kip1). One hundred
forty-nine of 163 DLBCLs could then be classified into
GCB group (pattern A), activated GCB group (pattern B),
and activated non-GCB group (pattern C) according to the
expression of CD10, BCL6, MUM1, and CD138. Of the
149 cases, 40 (26%) showed pattern A expression and were
grouped as GCB group, lower than the reported frequency
of the studies involving mostly Western population.
Compared with cases with pattern A, those with patterns B
(activated GCB group) and C (activated non-GCB group)
more often presented with more aggressive tumors and a
shorter survival time. These results indicate that most of
DLBCLs from Chinese patients can be classified into
prognostically different groups based on the antigenic
expression models using a panel of GCB- and ABC-
associatedmarkers.Polymerasechainreaction(PCR)analysis
of t(14;18) showed that 11 of 64 cases were t(14;18)-positive,
and most (10 of 11) of it occurred in the group with pattern A.
The translocation was significantly associated with the
expression of the Bcl-2 protein. The group with pattern B
demonstrated more frequent expression of Ki-67, cyclin D3,
and geminin and showed higher proliferative activity than the
group with pattern A. These findings suggest that high
proliferative activity of tumors with pattern B may be
associated with aggressive tumor behavior and poor clinical
outcome in patients with DLBCL [65].
As mentioned above, gene expression profiling on
frozen tissues has identified genes predicting outcome in
patients with DLBCL. Rimsza et al. were able to show that
a similar approach is feasible in paraffin tissue in almost all
209 analyzed cases. A practical approach was chosen by
Rimsza et al. who analyzed the methylation status of a large
series of cases from Tunisia and showed that, in 46 cases of
DLBCL, hypermethylated P16, VHL, DAPK, and SHP1
indicate a biologically aggressive phenotype and worse
prognosis. Hypermethylation of DAPK was found to be an
independent prognostic factor that may be used in conjunc-
tion with the conventional prognostic factors such as the IPI
and the germinal center status [66].
Bcl-2 associated athanogene-1 (BAG-1) is an antiapop-
totic protein as well as a regulator of cell growth. Ataollahi
studied 30 DLBCL cases and found nuclear expression in
all of the cases and cytoplasmic staining in 83%, whereas
nonneoplastic lymph nodes have little staining. This marker
revealed no prognostic impact [67].
Since it is relatively easy to perform miRNA profiling in
paraffin material, a large number of studies using this
approach can be expected in the coming months. Roehle et
al. showed that a miRNA profile obtained from 58 cases of
DLBCL, 47 follicular lymphomas, and seven nonneoplastic
lymph nodes can be used to create a highly reliable
diagnostic tree [68]. It remains to be seen when this
approach will replace hematopathologists who were still
being used as the gold standard in this study.
Hepatitis B virus (HBV) infection in DLBCL patients is
a common complication in China. However, the clinical
relevance of HBV infection with respect to DLBCL disease
stages and patient survival remains unclear. Compared with
the HBsAg-negative group, the HBsAg-positive DLBCL
group displayed a younger median onset age (46 vs.
51 years), more advanced stage at grade III/IV (58% vs.
42%), and more frequent hepatic dysfunction before (21%
vs. 5.5%) and during (49.4% vs. 16.6%) chemotherapy.
Female DLBCL patients exhibited a higher frequency of
HBsAg positivity. However, in both groups, the median
overall survival (OS) duration (55.8 vs. 66.8 months) and
response rates (91% vs. 90.4%) were similar. In the
HBsAg-positive DLBCL group, the poor prognostic factors
were advanced stage and hepatic dysfunction during
chemotherapy. The OS of HBsAg-positive patients with
hepatic dysfunction during chemotherapy was significantly
shorter than those without liver dysfunction and the OS
rates at 3 years were 48% and 72%, respectively. The use of
rituximab did not increase the rates of liver dysfunction in
HBsAg-positive DLBCL patients. This study suggests that
prophylactic treatment of HBV may be of great importance
in the cases of HBsAg-positive patients [69].
As was described in the previous review [4] extranodal
nasal type natural killer cell lymphoma (ENKL) is common
in East Asia. Xiang-Lan analyzed the expression of Skp2
and p27 proteins in 48 cases of ENKL and found that the
Skp2/p27 expression profile was an independent prognostic
factor for overall survival in this highly malignant disease
[70].
Staging
Many pathologists now use routine immunostaining on
bone marrow biopsies taken for staging lymphoma patients,
and in my experience, enhances recognition of not only
limited but also extensive but dispersed involvement by
lymphoma. Talaulikar et al. addressed this topic by studying
156 patients with DLBCL using CD20 and CD79a as
lymphoma markers. An additional 11% positive cases were
detected and these cases had a survival rate comparable to
that of H&E detected positive cases, supporting the routine
use of immunohistochemistry in evaluating bone marrow
biopsies for staging [71].
Bone marrow biopsies (BMB) are the conventional
staging method for assessing marrow involvement by
lymphoma. Morphological criteria provide basic data
determining their dignity, but concerning microfocal infil-
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immunoglobulin H (IgH) receptor rearrangement and
comparison of medullar and nodular lymphoma sites,
diagnostic reliability was improved. Employing nonnested
IgH rearrangement analysis with FR3A and JH consensus
primers, B cell clonality was assessed on glutardialdehyde
fixed, decalcified BMB with and without lymphoma
infiltration and on the corresponding lymph node speci-
mens. Comparison of lymph node tissues and BMB
revealed an identical pattern in 50% of the probes. In
25% of the cases, a single clonal peak derived from the
lymph node tissues was also observed in the BMB but was
surrounded by additional peaks. IgH FR3 PCR analysis is a
suitable tool to examine small lymphoid infiltrates in BMB,
and direct comparison with corresponding nodal lymphoma
can further facilitate estimation of their dignity [72].
Limited data have shown that immunostaining of bone
marrow biopsies improves staging in anaplastic large cell
lymphoma by highlighting limited involvement. This is
now common practice in such patients and required for
inclusion in multicenter trials. Based on a series of 41
patients, Weinberg et al. conclude that immunostaining with
CD30, EMA, ALK1, and granzyme has only minor
additional value above H&E staining [73].
The increasing application of multicolor flow cytometry
assays for staging and follow-up in MCL necessitates that
the specificity and sensitivity of this technique are eval-
uated. Bottacher et al. used standardized four-color flow
cytometry assay on 281 prospectively collected peripheral
blood and bone marrow samples from 98 patients with
MCL participating in a multicenter clinical trial and
compared the results to those obtained with conventional
clinical staging and consensus primer IGH PCR. Both
techniques detected about 10% more stage 4 patients than
conventional staging. The sensitivity of four-color flow
cytometry is comparable to that of IGH PCR at initial
staging but is less sensitive at follow-up after immunoche-
motherapy. Both techniques are highly valuable methods
for accurate initial staging [74].
Ancillary techniques
Using cytologic imprints from spinal lesions of 101
patients, Rezanko et al. were able to speed up the diagnostic
process so that early treatment could be installed preventing
further damage to the spinal cord. Especially the diagnosis
of plasmacytoma, lymphoma, or infectious disease was
made with great accuracy [75].
Flow cytometry is increasingly used for the classification
of lymphomas. Kost et al. describe the immunophenotype
of splenic marginal zone lymphoma (SMZL), nodal MZL
(NMZL), and extranodal MZL (MALT) and compared the
results to those of follicular lymphoma (FL). All 31 cases of
MZL (seven SMZL, six NMZL, 15 MALT, three MZL not
otherwise specified) and 31 cases of FL expressed CD19,
CD20, and CD45. Thirty-two percent of MZL and 77% of
FL expressed CD38. Expression of CD11c was seen in
57% of SMZL and 8% of other MZL (p<0.01). Statistically
significant differences in antigen expression between MZL
and FL were seen for CD10, CD11c, and CD38. MZL
expresses typical pan-B cell antigens. Expression of CD11c
is highly associated with SMZL. Although no specific
phenotype was found for MZL, levels of CD19 expression
in conjunction with CD11c and CD38 expression can
distinguish MZL from CD10 negative FL [76].
In a more general approach toward the value of flow
cytometry in diagnosing and classifying malignant lympho-
ma, Nguyen developed a Web-enabled relational database
integrated with decision-making tools for teaching flow
cytometric diagnosis of hematologic neoplasms. This data-
base has a knowledge base containing patterns of 44 markers
for 37 hematologic neoplasms. Immunophenotyping data
published in the scientific literature were incorporated into a
mathematical algorithm that is integrated to the database for
differential diagnostic purposes. The algorithm takes into
account the incidence of positive and negative expression of
each marker for each disorder. The algorithm developed in
this database shows significant improvement in diagnostic
accuracy over a previous database prototype. This Web-
based database is proposed to be a useful public resource for
teaching pathology trainees flow cytometric diagnosis [77].
Clonality testing is common in lymphoma diagnosis, but
pitfalls have to be known [78]. Since cHL is a clonal B cell
neoplasm, Chute et al. used the BIOMED-2 group set of
IGH multiplex on 42 cases of cH. The densities of Reed–
Sternberg cells/10 high-power field and CD30+ cells/10
high-power field were classified as low, intermediate, or
high. The quantities of background CD20+ B cells were
classified as low or high. DNA from formalin-fixed,
paraffin-embedded sections was used. Overall, 10/42
(24%) of the cHL samples were monoclonal and 7/42
(17%) were borderline monoclonal. Higher densities of
CD30+ cells and lower background B cells were statisti-
cally correlated with clonality. The BIOMED-2 primers
demonstrate IGH gene clonality in 24% to 40% of cHLs
without microdissection. In a subset of the cHL, the IGH
gene rearrangement analysis might be useful for diagnosis,
but can lead to confusion between cHLs and NHLs if used
as a discriminative criterion [79].
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